ArticlePathology oncology research : POR2014
Clinicopathologic significance of Sox2, CD44 and CD44v6 expression in intrahepatic cholangiocarcinoma.
Article in Pathology oncology research : POR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- mTranslational oncology · 2024Article
- Establishment and characterization of a novel cancer stem-like cell of cholangiocarcinoma.Cancer science · 2023Article
- Deletion ofCells · 2023Article
- Plasmon-Enhanced Single Extracellular Vesicle Analysis for Cholangiocarcinoma Diagnosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Advances of cancer-associated fibroblasts in liver cancer.Biomarker research · 2022Review
- Comparison of growth features and cancer stem cell prevalence in intrahepatic and extrahepatic cholangiocarcinoma cell lines.Clinical and experimental hepatology · 2022Article
- Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges.Cancer communications (London, England) · 2020Review
- Targeting cancer stem cells in cholangiocarcinoma (Review).International journal of oncology · 2020Review
- Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.International journal of molecular sciences · 2019Review
- Expression of CD44 and MDM2 in cholangiocarcinoma is correlated with poor clinicopathologic characteristics.International journal of clinical and experimental pathology · 2019Article
- Article
- SOX2 Promotes Cell Proliferation and Metastasis in Triple Negative Breast Cancer.Frontiers in pharmacology · 2018Article
- Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.International journal of oncology · 2017Article
- Biliary tract cancer stem cells - translational options and challenges.World journal of gastroenterology · 2017Review
- Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma.International journal of molecular sciences · 2017Review
- Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Nature reviews. Gastroenterology & hepatology · 2016Article
- Profiles of cancer stem cell subpopulations in cholangiocarcinomas.The American journal of pathology · 2015Article
- New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.Annals of gastroenterologyReview
- 3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Embryonic stem cells (ESC) and cancer stem cells (CSC) have a capacity for self-renewal and differentiation into multiple cell lineages. Sox2 plays a critical role in ESC and has been shown to participate in carcinogenesis and tumor progression in many human cancers. CD44 and CD44v6 are putative CSC markers and their association with tumor progression, metastasis, and tumor relapse after treatment has been demonstrated. We evaluated the immunoexpression of Sox2, CD44, and CD44v6 in 85 cases of Intrahepatic cholangiocarcinomas (IHCC) and assessed their prognostic significance. Sox2 expression showed a significant association with lymph node metastasis (p = 0.025), T4 stage (p = 0.046), and worse overall survival (p = 0.047). Greater expression of Sox2 was observed in IHCC with poor differentiation, vascular invasion, and stage IV, without statistical significance (p > 0.05). CD44 expression showed an association with periductal infiltrative type (p = 0.034), poor differentiation (p = 0.012), and vascular invasion (p = 0.009). CD44v6 expression was evident in patients with stage IV (p = 0.019). These results demonstrated that Sox2 expression is associated with aggressive behavior and poor overall survival in IHCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.